Cell clumps and particles are serious challenges in cell therapy, impacting safety and efficacy. Part 2 of Cell and Gene’s recent article takes a close look at these issues. That’s why we built the Aura system to tackle them head-on. Aura provides high-resolution imaging to automatically detect and analyze cell clumps, aggregates, and other inherent particles, making it easier to meet quality and regulatory standards. Read more: https://lnkd.in/ezEJjZsA
Halo Labs
Biotechnology Research
Burlingame, California 3,905 followers
Low Volume High-Throughput Cell, Gene, and Protein Therapeutic Quality
About us
We help our customers reduce development time and improve patient safety by quantifying stability, purity, and quality in protein therapeutics and cell and gene therapy products. Using the latest optics and innovative algorithms, Aura, our flagship product, can analyze and ID sub visible and visible particles, including protein, viral capsid, and cell aggregates. It utilizes a plate-based approach that enables high-throughput (up to 96 samples/run), low-volume (as little as 5 µL) particle analysis in a wide-range of samples from pre-formulation through quality control.
- Website
-
https://halolabs.com
External link for Halo Labs
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Burlingame, California
- Type
- Privately Held
- Founded
- 2011
- Specialties
- Biotechnology, Pharma QC, Analytical Instrumentation, and Biopharma
Locations
-
Primary
1828 El Camino Real
Suite 703
Burlingame, California 94010, US
Employees at Halo Labs
Updates
-
USP 788 defines standards for detecting subvisible particle in injectable drugs to ensure safety by identifying harmful contaminants. Compliance helps prevent recalls and protect patient health, but traditional particle analysis can be slow and labor-intensive. Aura and BMI streamline this process, delivering faster, more accurate results that meet USP 788 standards. With Aura’s advanced imaging and BMI’s precision detection, manufacturers can quickly identify even the smallest subvisible particles, improving quality control and efficiency. Learn how Aura & BMI can transform your particle analysis: https://lnkd.in/dcFkTgaq
Discover the Aura Family
https://www.halolabs.com
-
Filtration might not be the ultimate fix for removing particles during manufacturing. Surprisingly, it can actually lead to more aggregates over time—a big issue for cell-based therapies where filtration isn't feasible. That's why it's crucial to formulate biologics for long-term stability, beyond just filtration. We took a closer look at subvisible particles in samples immediately after filtration and over a two-week period. Want to know what we discovered? Read to find out: https://lnkd.in/gh7B56sD #particleanalysis #therapeutics #samplefiltration #LNP #lipidnanoparticles
App Note 21: Subvisible Particles: Why Don’t I Just Filter My Biologic Samples?
https://www.halolabs.com
-
With the rise of cell, gene, and protein therapeutics, understanding particle size distribution is more important than ever. Subvisible particles can jeopardize your product's success. Check out our blog for an in-depth guide on particle size analysis and see how Aura provides a more comprehensive picture. https://lnkd.in/gGNGV9MT
Complete Guide to Particle Size Distribution & Analysis
https://www.halolabs.com
-
At Halo Labs, we’re reflecting on what we’re most thankful for—our customers, partners, and colleagues who make every day rewarding. Wishing you all a holiday filled with warmth, good food, and time with those who matter most. Happy Thanksgiving! #happythanksgiving #team #lifeathalolabs
-
A recent article from Cell and Gene highlights a growing issue in the development of cell and gene therapies: the presence of both intrinsic and extrinsic particles. These particles, whether from the product itself or external contamination, can threaten patient safety and product integrity. Our Aura system offers a breakthrough solution, providing high-resolution, real-time analysis to detect and differentiate between these particles with unmatched clarity. Learn more: https://lnkd.in/gx_RVpvY
A "Particular" Problem For Cell Therapy Products, Part 1: Extrinsic And Intrinsic Particles
cellandgene.com
-
Next in our technology spotlight series: Side Illumination Membrane Imaging! Want to ensure your drug products are free from harmful particles? SIMI makes invisible contaminants visible, giving you the clarity needed to protect your products and patients. Learn more: https://lnkd.in/gR3sjWcw #particleanalysis #biologics #formulation #drugdevelopment
-
Did you miss our last webinar? Tune in as our Field Application Scientist, Dikran Khachadourian, walks you through innovative imaging and fluorescence microscopy techniques to characterize protein therapeutics products in stability studies. Watch now: https://lnkd.in/gRrE4wHC #webinar #proteins #proteinstability
GEN – Protein Therapeutics: An Automated Imaging Strategy for Elucidating Protein Stability
https://www.halolabs.com
-
A study in the Journal of Pharmaceutical Sciences introduced a novel method to evaluate protein aggregation. This rapid, small-volume approach uses our Backgrounded Membrane Imaging (BMI) to assess aggregation at air-water interfaces. BMI was particularly useful in this study due to its minimal volume requirement (25 μl), avoiding issues common with flow imaging techniques. It filters the sample through membrane wells, capturing all particles, and doesn't count air bubbles as particles. Read the full study here: https://lnkd.in/gnx_eUYY #biologics #particleanalysis
A Rapid, Small-Volume Approach to Evaluate Protein Aggregation at Air-Water Interfaces
jpharmsci.org
-
Is light obscuration enough to ensure the safety of your drug product? Not quite. Subvisible particle testing is crucial, but relying solely on light obscuration can leave gaps in analysis. Discover how complementary methods, like Background Membrane Imaging (BMI), can offer a more complete picture of drug safety. Read our blog now: https://lnkd.in/gSZpmXWm #particleanalysis #BMI
Light Obscuration May Not Be Enough to Detect SVPS in Your Drug Product
https://www.halolabs.com